



The power of EPKINLY makes sustained remission possible

Approved with R² to treat adults with **follicular lymphoma (FL)** that has returned or that didn't respond after **at least 1 treatment**

Treatment with the combination of EPKINLY plus lenalidomide and rituximab (R²), compared with R² alone, was studied in a clinical trial.

Results with EPKINLY and R²

- Patients treated with EPKINLY and R² had a **79% lower risk of disease progression or death** compared to R² alone
- 89%** (216 of 243 patients) **achieved remission**, compared to **74%** (181 of 245 patients) with R² alone
- At 1 year, an estimated 89%** of the 216 patients treated with EPKINLY and R² who **achieved remission** were still in **remission**, compared to **49%** of patients treated with R² alone



Actor portrayals.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

- follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
- follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- Infections and low blood cell counts**.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.



What's inside

| | |
|--|----|
| Key points about EPKINLY | 3 |
| Questions for your healthcare provider | 4 |
| How EPKINLY works | 5 |
| Results with EPKINLY | 6 |
| How EPKINLY is given | 8 |
| Important Safety Information | 10 |
| Resources and support | 12 |
| Tips for talking to your healthcare provider | 14 |

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.
Please see Medication Guide.

 **epkinly**[®]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Key points about the EPKINLY and R² treatment combination

The combination of lenalidomide and rituximab is commonly known as R², or "R squared."

- **EPKINLY and R² gave patients more time without passing away or their cancer getting worse (this is known as progression-free survival)**
 - Patients treated with EPKINLY and R² had a 79% lower risk of disease progression or death compared to R² alone
- **89% (216 of 243 patients) who received EPKINLY and R² achieved remission**
 - Compared to 74% (181 of 245 patients) with R² alone
- **EPKINLY and R² is not chemotherapy or stem cell therapy**
- **You can receive EPKINLY at your oncologist's office and start treatment as soon as you and your doctor are ready**
- **EPKINLY can cause serious side effects including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts**

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 22 of your first cycle of treatment. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with follicular lymphoma (FL) may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.



Keeping track of your top questions

While going through this brochure, keep track of any questions you might have for your healthcare provider. We've included some starter questions below.

How likely is it that the combination of EPKINLY and R² will put my cancer into remission?

How often will I receive EPKINLY and the other 2 medications?

What could my treatment experience be like with EPKINLY and R²?

If you have additional questions that you'd like to ask, list them here:

Question: _____

Answer: _____

Question: _____

Answer: _____

Question: _____

Answer: _____

Scan the QR code or visit
EPKINLY.com/2L-FL for more information




Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.
Please see Medication Guide.

epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg


EPKINLY harnesses the power of your own immune system

EPKINLY is a bispecific antibody designed to target 2 types of cells in your body—T cells and B cells




T Cells

T cells are immune cells that fight infections, as well as cancer cells.



B Cells

B cells are another type of immune cell, and in FL, some B cells can become cancerous and grow uncontrollably.



How EPKINLY Works

EPKINLY works by attaching to both your T cells and B cells, binding them together so that the T cells can attack and destroy B cells.



EPKINLY will be given with 2 other medications—lenalidomide and rituximab (also known as R²)

- These also **work with your immune system**, but target cancer differently than EPKINLY
- This treatment combination is **chemotherapy-free**

SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system, it **can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.**

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



EPKINLY and R² gave patients more time without passing away or their cancer getting worse

79%
lower risk

► Patients treated with EPKINLY and R² had a **79% lower risk of disease progression or death** (progression-free survival) compared to R² alone

How was EPKINLY studied?

Treatment with the combination of EPKINLY and R², compared with R² alone, was studied in a clinical trial of 488 patients with FL whose cancer returned or didn't respond after at least 1 treatment.

SELECT IMPORTANT SAFETY INFORMATION


Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.


epkinly
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

89% of patients achieved remission, with most reaching complete remission

Powerful results with EPKINLY and R²



Most patients had no signs of cancer after taking EPKINLY and R²



SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.



You can receive EPKINLY and R² at your oncologist's office

You can receive EPKINLY and R² at your oncologist's office. This allows you to start treatment as soon as you and your doctor are ready.

Dosing schedule for EPKINLY and R²

| | EPKINLY (Injection) | R ² | Lenalidomide (Pill) |
|-------------|------------------------|----------------|---|
| Weeks 1-4 | Weekly* | Weekly | |
| Weeks 5-12 | Weekly | Every 4 weeks | |
| Weeks 13-20 | | | Daily (for the first 21 days of each month) |
| Weeks 21-48 | Every 4 weeks | Not given | |

Step-up dosing of EPKINLY is designed to help you safely adjust to treatment due to the risk of CRS

*During the first 3 weeks of treatment, you will receive smaller "step-up" doses of EPKINLY than the doses you will receive in week 4 and for the rest of your treatment.

- Before and for 3 days after each dose of EPKINLY in your first 4 weeks of treatment, you will receive other medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS in later doses of EPKINLY
- You may need to be hospitalized after receiving your first full dose of EPKINLY due to the risk of CRS
- You may have side effects during treatment. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts. Your treatment may be temporarily or completely stopped if you develop certain side effects
- If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule

CRS=cytokine release syndrome.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.
Please see Medication Guide.



Completing the approximately 11-month treatment with EPKINLY and R² may give you more time without passing away or your cancer getting worse

- Your treatment could be delayed or stopped if you have certain side effects

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

- follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
- follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. Your first full dose of EPKINLY will be given on day 22 of your first cycle of treatment. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with follicular lymphoma (FL) may need to be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems.** If you have any symptoms that impair consciousness, **do not** drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion.

Please see additional Important Safety Information on pages 11.
Please see Medication Guide.


epkinly
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

- **Low blood cell counts**, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. **The most common severe abnormal laboratory test results with EPKINLY when used alone** include decreased white blood cells, decreased red blood cells, and decreased platelets.



The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. **The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab** include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

MyNavCare Patient Support® is here to support you



With MyNavCare, you can receive personalized support throughout your treatment journey with EPKINLY from a dedicated team that cares



A partner on your treatment journey with EPKINLY

Your healthcare provider is your main source for treatment information. With MyNavCare, you gain access to additional resources and medication information.

- Dedicated support throughout your treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistance foundation information†
- Genmab Patient Assistance Program



Ongoing personalized support

Your **Patient Engagement Liaison**‡ provides ongoing support throughout treatment. They're dedicated to you, helping to:

- Provide general information about your condition
- Connect you to third-party organizations that may be able to help
- Offer resources for you and your Care Partners

*Based on eligibility requirements and Terms and Conditions. Federal health care program (FHCP) patients are not eligible for MyNavCare copay support.

†Eligibility criteria are determined by each independent third-party foundation. MyNavCare does not determine eligibility and cannot guarantee foundations will offer assistance.

‡MyNavCare Patient Engagement Liaisons are part of the MyNavCare Patient Support Program and do not provide medical advice or work under the direction of the prescribing healthcare providers. They are trained to direct patients to speak with their healthcare provider about any treatment-related questions.

Contact a **MyNavCare Support Specialist** by calling **1-866-NAV-CAR1** (1-866-628-2271), Monday-Friday, 8 AM – 8 PM ET. You can also scan the QR code or visit www.MyNavCare.com to learn more.



Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg



Support for you and your Care Partner

Here are some organizations that can help Patients and Care Partners connect with others, and provide information and resources throughout treatment.



CancerCare

www.cancercare.org
800-813-HOPE (4673)



American Cancer Society

www.cancer.org
800-227-2345



Lymphoma Research Foundation

www.lymphoma.org
800-500-9976

Blood Cancer United

www.bloodcancerunited.org
800-955-4572



Family Reach

www.familyreach.org
857-233-2764



Follicular Lymphoma Foundation

www.theflf.org
info@theflf.org

Information for Care Partners

As a Care Partner, you have become an integral part of your loved one's healthcare team.

Some responsibilities you may take on during your loved one's treatment:

- **Decision-making:** Researching clinical trials and treatment options, helping to consider treatment choices, and being an advocate for your loved one
- **Emotional:** Encouraging your loved one to share their feelings and helping them feel supported
- **Treatment support:** Helping watch for potential side effects, attending appointments, and ensuring they have what they need throughout their treatments
- **Logistical:** Scheduling and driving them to appointments, running errands, and assisting with daily needs

There are many available resources that may be helpful to patients, families, and Care Partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.

Please see **Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.**
Please see **Medication Guide.**



CONSIDERING EPKINLY

Is EPKINLY right for you?

If you are considering treatment with the combination of EPKINLY and R², use these 2 pages to help you think about this option and have an informed discussion with your doctor.

My previous treatments

Use this chart to write notes about your previous treatments so you can discuss them with your healthcare provider.

| Previous treatment | What was your experience with this treatment? (eg, how you responded, side effects, dosing, how it was given) |
|--------------------|--|
| | |
| | |
| | |
| | |

My current medications

When considering a new treatment, you may have questions about your current medications:

My treatment goals

Write down what's important to you as you consider your next treatment.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.
Please see Medication Guide.


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Questions about EPKINLY

Use this chart to take notes during your next appointment when discussing EPKINLY with your healthcare provider.

| EPKINLY | Notes |
|------------------------------|-------|
| How it works | |
| Potential treatment benefits | |
| How it is given | |
| Potential treatment risks | |



Patient/Care Partner tip: Consider asking your healthcare provider if you can record the conversation on your device, so you can reference it at a later time.


Please see **Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11.**
Please see [Medication Guide](#).


epkinly®
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Compared to R² alone

EPKINLY powers complete remission for more patients

Treatment with the combination of EPKINLY and R², compared with R² alone, was studied in a clinical trial of 488 patients. 89% (216 of 243 patients) achieved remission, compared to 74% (181 of 245 patients) with R² alone.



What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with:

- follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab
- follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments.

It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or lead to death.
- **Neurologic problems** that can be serious, and can be life-threatening and lead to death.
- **Infections and low blood cell counts**.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 10-11. Please see Medication Guide.

Scan the QR code or visit
EPKINLY.com/2L-FL for more information



Distributed and marketed by Genmab US Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY and MyNavCare Patient Support are registered trademarks of Genmab A/S.
All other trademarks and registered trademarks are the property of their respective owners.
©2026 Genmab A/S and AbbVie. All rights reserved.
01/2026 COM-US-EPK-0001850

